Last updated: September 3, 2026
SEMGLEE is the U.S. brand for insulin glargine-yfgn, developed by Biocon Biologics and commercialized in the United States through Viatris before Biocon acquired Viatris’ biosimilars business. The product received FDA approval in 2021 as the first interchangeable biosimilar insulin, giving it a substitution advantage over non-interchangeable competitors.
SEMGLEE’s commercial performance depends on three factors: insulin pricing pressure, payer and pharmacy-benefit-manager access, and substitution against Sanofi’s Lantus. Its market position is stronger than a conventional biosimilar because pharmacists may substitute an interchangeable product under applicable state law without contacting the prescriber. The commercial challenge is that insulin glargine is already a mature, heavily rebated category with several competing products.
What is SEMGLEE and who owns the product?
SEMGLEE is insulin glargine-yfgn, a long-acting basal insulin for improving glycemic control in adults and children with diabetes mellitus. It is biosimilar to and interchangeable with Lantus, whose active ingredient is insulin glargine.
| Item |
Details |
| Product |
SEMGLEE |
| Active ingredient |
Insulin glargine-yfgn |
| Reference product |
Lantus, insulin glargine |
| FDA pathway |
Section 351(k) biosimilar application |
| FDA approval |
July 28, 2021 |
| Interchangeability |
Granted by FDA in July 2021 |
| U.S. NDA/BLA |
BLA 761201 |
| Initial commercial partners |
Viatris and Biocon Biologics |
| Current biosimilars owner |
Biocon Biologics |
| Primary market |
U.S. insulin glargine market |
| Dosage forms |
100 units/mL vial and prefilled pen presentations |
The product was initially marketed through two channels: a branded SEMGLEE product and an unbranded insulin glargine-yfgn product. The unbranded version was intended to compete more directly on net price, while the SEMGLEE brand retained visibility with prescribers and pharmacies.
Biocon Biologics acquired Viatris’ global biosimilars business in a transaction that closed in 2023. The deal transferred commercial control of SEMGLEE and other biosimilar products to Biocon Biologics, while Viatris remained involved in certain transition and regional arrangements. Biocon Biologics is a subsidiary of Biocon Ltd. [1][2]
How large is the insulin glargine market?
Insulin glargine is one of the largest basal-insulin markets and includes originator, follow-on, biosimilar and authorized-generic products.
| Competitor |
Company |
Product type |
U.S. status |
| Lantus |
Sanofi |
Reference insulin glargine |
Originator |
| Toujeo |
Sanofi |
Concentrated insulin glargine U-300 |
Branded follow-on |
| Basaglar |
Eli Lilly and Boehringer Ingelheim |
Follow-on insulin glargine |
Established competitor |
| Rezvoglar |
Eli Lilly |
Biosimilar insulin glargine-aglr |
FDA-approved biosimilar |
| SEMGLEE |
Biocon Biologics |
Interchangeable biosimilar insulin glargine-yfgn |
FDA-approved interchangeable biosimilar |
| Unbranded insulin glargine-yfgn |
Biocon Biologics |
Unbranded version of SEMGLEE |
Commercially available |
| Insulin glargine-yfgn |
Biocon Biologics |
Biosimilar product |
U.S. substitution and payer dependent |
The category has moved from a single-originator model to a multi-product market. Lantus remains commercially important, but its position is exposed to lower-priced products, mandatory rebates and formulary exclusions.
Sanofi reported declining Lantus sales as competition increased. Global Lantus sales were approximately €2.4 billion in 2023, down from prior-year levels, reflecting biosimilar and follow-on competition, pricing pressure and portfolio migration toward Toujeo. [3]
The total U.S. opportunity is less than the gross sales of Lantus suggest because net prices are materially below list prices. Rebates paid to PBMs, health plans and government programs reduce manufacturer revenue and make market share more important than prescription volume alone.
What is SEMGLEE’s FDA regulatory status?
SEMGLEE was approved under the FDA’s biosimilar pathway and received an interchangeable designation. FDA determined that insulin glargine-yfgn is biosimilar to Lantus and that switching between the products does not create greater risk than using Lantus without switching. [4]
The interchangeability designation has commercial value for retail pharmacy substitution. It does not guarantee automatic substitution in every state. State pharmacy laws, payer formularies, plan contracts and dispensing practices govern the practical effect.
SEMGLEE’s regulatory position is distinct from a generic drug approval:
- It is licensed under the Public Health Service Act.
- It is listed in FDA’s Purple Book rather than as a conventional small-molecule generic in the Orange Book.
- It does not rely on a Paragraph IV certification.
- Its substitution rights derive from the FDA interchangeability designation and state law.
- Its commercial access still depends heavily on payer contracts.
Rezvoglar was approved as a biosimilar to Lantus but was not initially positioned with the same interchangeable status as SEMGLEE. That distinction gave SEMGLEE a first-mover advantage in pharmacy-level substitution.
When did SEMGLEE lose exclusivity?
SEMGLEE is not protected by conventional new-drug exclusivity comparable to a novel small molecule. Its market entry was based on biosimilar competition against Lantus, and its main commercial protection came from regulatory approval, interchangeability, manufacturing capability, supply reliability and payer positioning.
The key regulatory dates are:
| Date |
Event |
| July 28, 2021 |
FDA approved insulin glargine-yfgn as biosimilar to Lantus |
| July 28, 2021 |
FDA granted interchangeable status |
| July 2021 |
U.S. commercial launch began |
| 2022 |
Viatris and Biocon expanded branded and unbranded commercialization |
| September 2023 |
Biocon completed acquisition of Viatris’ biosimilars business |
| 2023 onward |
Biocon became the principal commercial owner of the biosimilar platform |
SEMGLEE’s commercial exclusivity is therefore best understood as an early-entry advantage rather than a long statutory monopoly. Competing insulin glargine products can enter once their own regulatory and patent positions permit.
What patents protect SEMGLEE and does it face Paragraph IV risk?
SEMGLEE does not have the conventional Orange Book patent framework associated with small-molecule drugs. FDA biosimilar products are generally evaluated through the Purple Book, and Paragraph IV litigation is not the standard pathway for challenging a biosimilar product.
The relevant patent risks are broader:
- Reference-product patents. Sanofi’s Lantus and delivery-device patents shaped the timing of biosimilar entry.
- Manufacturing patents. Insulin production relies on recombinant-cell systems, fermentation, purification and formulation processes.
- Device patents. Pen injectors, cartridge assemblies and dose-delivery mechanisms may carry separate intellectual-property protection.
- Formulation patents. Stabilizers, concentrations and storage characteristics may create additional rights.
- Process trade secrets. Yield, purification and quality-control methods can be commercially important even without broad patent protection.
- Regional patent rights. The applicable patent landscape varies across the United States, Europe, emerging markets and regulated tender markets.
Publicly visible litigation involving SEMGLEE has not produced the same recurring Orange Book litigation profile seen with branded small-molecule products. The principal legal risk is competitive patent enforcement around manufacturing, devices and reference-product technologies rather than a conventional Paragraph IV challenge to SEMGLEE.
What formulations and delivery systems does SEMGLEE have?
SEMGLEE is available in the standard U-100 concentration used for basal insulin therapy. Product presentations include vials and disposable prefilled pens.
The formulation and presentation are commercially important because insulin competition is not based only on active ingredient similarity. Prescribers, patients, pharmacies and payers evaluate:
- Pen versus vial availability.
- Dose accuracy and ease of use.
- Injection-device familiarity.
- Storage and handling requirements.
- Patient switching protocols.
- Supply continuity.
- Contracted net price.
- Manufacturer assistance programs.
Toujeo competes in a different concentration segment with U-300 insulin glargine. It can offer a lower injection volume for some patients and is therefore not a direct one-for-one substitute for SEMGLEE in every clinical or commercial setting.
How has SEMGLEE’s financial trajectory developed?
Viatris reported strong early growth after launch, although SEMGLEE’s standalone economics were affected by launch expenses, channel discounts and the cost of establishing payer access.
Viatris reported approximately $278 million in SEMGLEE revenue in 2022, up sharply from its partial-year 2021 performance. The product became one of the most visible growth assets in Viatris’ biosimilars portfolio before the sale of the biosimilars business to Biocon. [1]
After the transaction, Biocon reported biosimilars revenue at the business-unit level rather than consistently reporting a separate SEMGLEE revenue line in public financial releases. This makes direct year-to-year comparison more difficult. The commercial trajectory can be summarized as follows:
| Period |
Financial development |
| 2021 |
Partial-year U.S. launch; initial revenue ramp |
| 2022 |
Rapid expansion under Viatris and Biocon; approximately $278 million reported by Viatris |
| 2023 |
Ownership transition to Biocon Biologics; continued U.S. and international commercialization |
| FY2024 |
Biocon Biologics reported growth in its broader biosimilars business, but SEMGLEE was not consistently disclosed as a standalone revenue category |
| 2024 onward |
Greater pricing pressure as insulin glargine competition and payer negotiations mature |
The most important financial change is the shift from launch-phase growth to category-management economics. Initial revenue growth came from conversion of Lantus prescriptions and favorable positioning for an interchangeable biosimilar. Later growth depends on maintaining formulary status while accepting lower net prices.
SEMGLEE’s gross sales can rise even as its net revenue per unit falls if volume gains exceed rebate growth. The reverse can also occur: prescription share may increase while revenue declines because of aggressive contracting.
Which companies are challenging SEMGLEE?
SEMGLEE faces pressure from both direct and indirect competitors.
Direct biosimilar competition
Rezvoglar is the clearest direct U.S. competitor. Its presence limits SEMGLEE’s ability to maintain premium pricing solely on the basis of biosimilar status. Future interchangeable insulin glargine products could reduce the value of SEMGLEE’s first-mover advantage.
Originator and follow-on competition
Lantus retains brand recognition, accumulated clinical experience and established payer relationships. Basaglar competes as a lower-cost follow-on product and has built substantial formulary presence. Toujeo protects Sanofi’s insulin glargine franchise by offering a concentrated formulation with different dosing characteristics.
Broader basal-insulin competition
Semglee also competes indirectly with:
- Insulin degludec, marketed as Tresiba by Novo Nordisk.
- NPH insulin.
- Other basal-insulin products used in public-sector tenders.
- Emerging low-cost insulin products in international markets.
The competitive set differs by country. In the U.S., PBM contracts and interchangeability are central. In Europe and emerging markets, hospital tenders, national reimbursement policies, local manufacturing and price caps play a larger role.
What is the impact of Medicare and insulin price controls?
The Inflation Reduction Act established a $35 monthly insulin cost-sharing cap for many Medicare beneficiaries. The cap reduces patient out-of-pocket expense but does not automatically increase manufacturer revenue. It can intensify payer negotiations because plans have stronger incentives to steer patients toward preferred insulin products while preserving affordability for beneficiaries. [5]
Commercial plans also use formulary exclusions and preferred-product strategies. A biosimilar manufacturer may need to provide substantial rebates to obtain preferred status against Lantus, Basaglar or Rezvoglar.
This creates a three-level pricing structure:
| Price level |
Commercial relevance |
| List price |
Public reference point; limited indicator of manufacturer economics |
| Gross sales |
Includes contracted and channel effects before some deductions |
| Net revenue |
More relevant measure after rebates, discounts and returns |
For SEMGLEE, net price and formulary access are more important than the nominal discount to Lantus.
How strong is the SEMGLEE commercial and manufacturing position?
SEMGLEE has a strong regulatory position but a mixed commercial position.
Strengths
- First interchangeable biosimilar insulin approved by FDA.
- Established reference-product comparability to Lantus.
- Ability to compete through pharmacy substitution where state law permits.
- Biocon’s insulin manufacturing capabilities and global biologics infrastructure.
- Viatris’ former U.S. commercial and payer infrastructure.
- Availability of both branded and unbranded positioning.
Constraints
- Mature insulin glargine demand with limited category growth.
- Heavy rebate dependence.
- Multiple established competitors.
- Manufacturing complexity and quality requirements.
- Supply-chain sensitivity.
- Limited public disclosure of standalone post-2023 revenue.
- State-by-state variation in substitution rules.
- Potential margin erosion from tendering and payer contracting.
Manufacturing is a meaningful barrier to entry. Recombinant insulin requires validated biological production, purification, sterile filling, analytical comparability and reliable cold-chain distribution. Those requirements limit the number of credible entrants, but they do not prevent competition from large insulin manufacturers.
What generic launch risks exist for SEMGLEE?
The principal launch risk is not a sudden traditional generic substitution event. It is gradual share erosion through payer-led switching.
Potential scenarios include:
| Scenario |
Commercial effect |
| Preferred formulary status retained |
Volume growth with controlled net-price erosion |
| Non-preferred status |
Lower prescription growth and higher rebate requirements |
| Multiple interchangeable competitors |
Faster substitution and margin compression |
| Lantus price response |
Lower category pricing and reduced SEMGLEE spread |
| Manufacturing disruption |
Temporary loss of pharmacy and payer confidence |
| Strong unbranded adoption |
Higher volume but lower brand realization |
| Tender-market expansion |
Large volume gains with low unit margins |
Biocon’s ability to coordinate branded SEMGLEE, unbranded insulin glargine-yfgn and international tender strategies will determine whether volume growth offsets declining unit economics.
What is the outlook for SEMGLEE revenue and market share?
SEMGLEE is likely to remain a meaningful biosimilar-insulin franchise, but its growth rate should moderate from the launch period.
The base-case trajectory is:
- Continued conversion from Lantus and other basal insulins.
- Increasing use of unbranded insulin glargine-yfgn in price-sensitive channels.
- Lower average net selling price as payers negotiate against multiple products.
- Greater dependence on manufacturing reliability and supply contracts.
- Rising importance of non-U.S. markets and government tenders.
- Pressure on branded revenue as the category becomes interchangeable in practice.
The product’s strongest asset is its interchangeable designation. Its largest weakness is that insulin glargine is a mature category where payers can capture much of the savings through rebates. SEMGLEE can generate durable revenue, but long-term value will depend on volume, manufacturing cost and contract discipline rather than on premium pricing.
Key Takeaways
- SEMGLEE is insulin glargine-yfgn, the first FDA-approved interchangeable biosimilar insulin.
- Biocon Biologics now controls the principal commercial rights after acquiring Viatris’ biosimilars business.
- Viatris reported approximately $278 million of SEMGLEE revenue in 2022.
- Post-transaction financial reporting generally provides less standalone SEMGLEE revenue detail.
- Lantus, Basaglar, Toujeo and Rezvoglar are the main U.S. competitive products.
- Interchangeability creates a substitution advantage, but state law and payer formularies determine its practical value.
- Paragraph IV litigation is not the primary legal framework because SEMGLEE is a biologic licensed under the 351(k) pathway.
- The main financial risk is net-price erosion from PBM contracting and expanding biosimilar competition.
- Manufacturing scale, quality consistency and supply reliability are central barriers to entry.
- SEMGLEE’s long-term trajectory is more likely to be volume-led than price-led.
FAQs About SEMGLEE Market Dynamics and Financial Performance
Is SEMGLEE cheaper than Lantus?
SEMGLEE is generally positioned as a lower-cost alternative to Lantus, but the realized savings depend on list price, rebates, formulary contracts, pharmacy margins and patient assistance programs.
Can a pharmacist automatically substitute SEMGLEE for Lantus?
Substitution may be permitted because SEMGLEE is interchangeable, but the result depends on the pharmacy law of the applicable state and the patient’s payer requirements.
Is SEMGLEE a generic insulin?
No. SEMGLEE is a biosimilar biologic, not a conventional small-molecule generic. It was approved under the FDA’s 351(k) biosimilar pathway.
Does SEMGLEE have an Orange Book listing?
SEMGLEE is regulated as a biologic and is primarily tracked through FDA’s Purple Book rather than the conventional Orange Book framework used for small-molecule drugs.
Who manufactures SEMGLEE?
Biocon Biologics is the principal manufacturer and commercial owner of SEMGLEE. The product originated from the Biocon-Viatris biosimilars collaboration, with commercial ownership transferring to Biocon after the 2023 transaction.
References
- Viatris Inc. (2023). 2022 annual report. U.S. Securities and Exchange Commission.
- Biocon Limited. (2023). Acquisition of Viatris’ global biosimilars business. Biocon Investor Relations.
- Sanofi. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2021). FDA approves first interchangeable biosimilar insulin product.
- Centers for Medicare & Medicaid Services. (2023). Medicare insulin savings model and Inflation Reduction Act insulin cost-sharing provisions.
